ERBB2 and neoplasm: In line with this, it is plausible that adding additional agents to inhibit tumor growth with distinct modes of action from TKIs, such as chemotherapeutic agents, to existing combination strategies with TKIs plus anti-HER2 mAbs may offer more choices to treat these two aggressive tumors.